NCT00514371 - A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Multiple Myeloma

Interventions

DRUG

tanespimycin

High dose

DRUG

Bortezomib

Mid dose, and low dose

Trial Locations (11)

Local Institution, New York

Local Institution, New York

Local Institution, Pittsburgh

Local Institution, Baltimore

Local Institution, Winston-Salem

Local Institution, Columbia

Local Institution, Augusta

Local Institution, Omaha

Local Institution, San Francisco

Local Institution, Berkeley

Local Institution, Boston